[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 87 of about 87
1. Uzquiano MC, Prieto VG, Nash JW, Ivan DS, Gong Y, Lazar AJ, Diwan AH: Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol; 2008 May;21(5):540-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma exhibits reduced actin expression.
  • Basal cell carcinoma is the most common malignancy in Caucasian individuals.
  • Metastatic basal cell carcinoma is extremely rare (with a rate estimated as 0.03%).
  • Actin has been detected in aggressive forms of basal cell carcinoma, but their expression in metastatic lesions is not known.
  • We compared the expression of actin and actin-related cytoskeletal proteins in relatively less aggressive basal cell carcinoma (nodular), aggressive basal cell carcinoma (infiltrative/morpheaform), and metastatic basal cell carcinoma.
  • We studied 12 cases of nodular basal cell carcinoma, 10 cases of infiltrative basal cell carcinoma, and 10 cases of metastatic basal cell carcinoma with immunohistochemistry for alpha-smooth muscle actin, calponin, myosin, and E-cadherin.
  • Five of the ten patients with metastatic basal cell carcinoma had an antecedent history of radiotherapy.
  • Actin was present in 3 of 12 (25%) of the nodular, all 10 of the infiltrative, and 3 of 10 of the metastatic basal cell carcinomas (P<0.05 for metastatic vs infiltrative and nodular vs infiltrative).
  • Calponin was present in 50% of the nodular, 60% of the infiltrative, and 30% of the metastatic basal cell carcinomas (not statistically significant).
  • E-cadherin was present in 75% of the nodular, 70% of the infiltrative, and all of the metastatic basal cell carcinomas (P<0.05 for metastatic vs nodular).
  • [MeSH-major] Actins / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223552.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Cadherins; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / calponin; EC 3.6.4.1 / Myosins
  •  go-up   go-down


2. Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M: Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol; 2008 Feb;21(2):178-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
  • Even though immunohistochemical comparisons of microcystic adnexal carcinoma vs infiltrative basal cell carcinoma and desmoplastic trichoepithelioma exist, they are mostly restricted to the use of a single stain.
  • In addition, a comparison with squamous cell carcinoma has not been reported previously.
  • In this study, we compare the expression of cytokeratin (CK) 15, CK7, CK20, CK903, carcinoembryonic antigen (CEA), CD10, CD15 and BerEP4 in 13 microcystic adnexal carcinoma, eight desmoplastic trichoepithelioma, 10 infiltrative basal cell carcinoma, and eight squamous cell carcinoma of which five exhibited ductal differentiation.
  • We found that the majority of microcystic adnexal carcinoma (92%) and desmoplastic trichoepithelioma (100%) cases expressed CK15 while the infiltrative basal cell carcinoma and squamous cell carcinoma cases were all negative.
  • Forty percent of infiltrative basal cell carcinoma expressed CK7; while only two microcystic adnexal carcinoma cases (15%) and one squamous cell carcinoma with ductal differentiation (12%) expressed CK7 in the remaining three tumor categories.
  • While the neoplastic cells were negative, luminal staining of ductal structures was noted for CK7, CD15 and CEA in some of the microcystic adnexal carcinoma, desmoplastic trichoepithelioma and squamous cell carcinoma with ductal differentiation cases.
  • Sixty percent of infiltrative basal cell carcinoma, 31% of microcystic adnexal carcinoma, and 25% of squamous cell carcinoma express CD10.
  • BerEP4 expression was noted in 38% of microcystic adnexal carcinoma, 57% of desmoplastic trichoepithelioma, 100% of infiltrative basal cell carcinoma, and 38% of squamous cell carcinoma.
  • In conclusion, we found CK15 to be a useful marker in distinguishing microcystic adnexal carcinoma from infiltrative basal cell carcinoma and squamous cell carcinoma with ductal differentiation.
  • Our experience indicates that microcystic adnexal carcinoma and desmoplastic trichoepithelioma have a similar immunohistochemical profile that is, CK15+ and BerEP4+/-; thus, additional studies are needed to separate these two entities.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Skin Appendage / chemistry. Head and Neck Neoplasms / chemistry. Immunohistochemistry / methods. Skin Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Humans. Keratin-15 / analysis. Male. Middle Aged

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065959.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-15; 0 / human epithelial antigen-125
  •  go-up   go-down


3. Vasconcelos HM Jr, Almeida AL, Sagawa A, Carvalho RM, Avila MP: [An advanced case of basosquamous carcinoma of the orbit: case report]. Arq Bras Oftalmol; 2009 Nov-Dec;72(6):819-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of basosquamous carcinoma of the orbit: case report].
  • [Transliterated title] Carcinoma basoescamoso avançado de órbita: relato de caso.
  • Basosquamous carcinoma is a rare tumor with features of both basal cell and squamous cell carcinoma, linked by a transition area.
  • It is a rare epithelial neoplasm with a tendency for local recurrence.
  • It also has a high incidence of distant metastasis, a condition that differentiates it from the basal cell carcinoma.
  • In this case, the slow course of the infiltrative lesion associated to patient non-compliance to treatment led to a poor prognosis.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Orbital Neoplasms / pathology. Patient Compliance

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098906.001).
  • [ISSN] 1678-2925
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Abbas O, Richards JE, Mahalingam M: Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol; 2010 Nov;23(11):1535-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
  • Microscopically, differentiating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma can be difficult as both show 'islands and strands of basaloid cells embedded in a sclerotic stroma'.
  • More recently, it has been identified as a marker of reactive tumor stromal fibroblasts, as it is reportedly selectively expressed in peritumoral stromal fibroblasts of multiple epithelial cancers including cutaneous malignancies such as basal cell carcinoma.
  • Given this, we sought to ascertain the use of fibroblast-activation protein in distinguishing morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
  • Immunohistochemical staining for fibroblast-activation protein was performed on desmoplastic trichoepithelioma (n=25) and morpheaform/infiltrative basal cell carcinoma (n=25), with the control group comprising scars from reexcision specimens (n=10).
  • Of interest, fibroblast-activation protein expression was observed in peritumoral fibroblasts of all cases of morpheaform/infiltrative basal cell carcinoma (25 of 25, 100%) but not in any cases of desmoplastic trichoepithelioma (0 of 25, 0%).
  • A gradient of fibroblast-activation protein expression was observed in morpheaform/infiltrative basal cell carcinoma with more intense expression noted in fibroblasts abutting the tumor cells, a less intense expression in the distal peritumoral stromal portion, and minimal to loss of expression in adjacent normal tissue.
  • In summary, findings from this study underscore the use of fibroblast-activation protein as a histologic adjunct in confidently differentiating morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Fibroblasts / enzymology. Gelatinases / analysis. Membrane Proteins / analysis. Serine Endopeptidases / analysis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Boston. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711172.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


5. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma. Actas Dermosifiliogr; 2010 Sep;101(7):622-628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma.
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • Histology showed that 64% of the tumors were infiltrative or micronodular carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y AEDV. All rights reserved.
  • (PMID = 28709544.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliograficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Análisis de costes / Cirugía micrográfica / Cost analysis / Cost-effectiveness / Coste/beneficio / Micrographic surgery / Mohs
  •  go-up   go-down


6. Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, Thomas GJ: alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res; 2008 May 1;68(9):3295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
  • Basal cell carcinoma (BCC) is the most prevalent cancer in the Western world and its incidence is increasing.
  • In contrast, the "high-risk" morphoeic variant, which causes significant morbidity, has an infiltrative growth pattern, and is so-called because of its densely fibrous stroma.
  • As alpha v beta 6 is capable of promoting both carcinoma invasion and fibrosis, we examined the expression of this integrin in BCCs and found that the morphoeic type showed significantly higher alpha v beta 6 expression than the nodular type (P = 0.0009).
  • These cells expressed alpha v beta 6 and were invasive, although inhibition of alpha v beta 6 had no direct effect on cell invasion.
  • These data suggest that alpha v beta 6-dependent transforming growth factor-beta1 activation induces both the infiltrative growth pattern and fibrotic stroma so characteristic of morphoeic BCC.
  • [MeSH-major] Antigens, Neoplasm / physiology. Carcinoma, Basal Cell / pathology. Integrins / physiology. Skin Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Animals. Antibodies / pharmacology. Cell Movement / genetics. Cells, Cultured. Hepatocyte Growth Factor / metabolism. Humans. Keratinocytes / metabolism. Kruppel-Like Transcription Factors / genetics. Kruppel-Like Transcription Factors / metabolism. Mink. Neoplasm Invasiveness. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Proto-Oncogene Proteins c-met / metabolism. RNA, Small Interfering / pharmacology. Transcription Factors / genetics. Transcription Factors / metabolism. Transforming Growth Factor beta1 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451156.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Integrins; 0 / Kruppel-Like Transcription Factors; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / integrin alphavbeta6; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


7. Elamin I, Zecević RD, Vojvodić D, Medenica L, Pavlović MD: Cytokine concentrations in basal cell carcinomas of different histological types and localization. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Jun;17(2):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine concentrations in basal cell carcinomas of different histological types and localization.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin tumor.
  • Cytokines as major mediators of the immune system have been shown to play an important role in biology of the neoplasm with the general predomination of Th2 cytokines, whereas IFN-?
  • OBJECTIVE: We were interested in comparing cytokine levels in BCC and cutaneous squamous cell tumors with BCC of different localization and histological subtypes.
  • MATERIAL AND METHODS: Explants from freshly excised BCC from 18 patients, and cutaneous squamous cell tumors (solar keratoses and Bowen's disease) from 9 patients were cultivated for 24 h.
  • RESULTS: Tissue explants of BCC contained significantly higher concentrations of IL-1beta, IL-4, IL-5, and IL-6 compared to those of squamous cell tumors.
  • Interleukin-6 concentrations were higher in aggressive BCC variants (infiltrative and micronodular), but the difference was not statistically significant (p = 0.068).
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Cytokines / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / chemistry. Female. Humans. Interleukin-4 / analysis. Interleukin-5 / analysis. Male. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709290.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-5; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4
  •  go-up   go-down


8. Hamada S, Kersey T, Thaller VT: Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome. Br J Ophthalmol; 2005 Aug;89(8):992-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome.
  • AIM: To analyse the outcome of basal cell carcinoma (BCC) excision in a subregional (non-Mohs) oculoplastic service.
  • There were no recurrences for non-infiltrative BCCs.
  • All recurrences were in infiltrative BCCs.
  • CONCLUSIONS: Non-infiltrative BCC excision with 4 mm margins gave a zero recurrence rate.
  • Infiltrative BCCs should be followed up indefinitely.
  • Previous recurrence and infiltrative histology have predictive value for recurrence.
  • [MeSH-major] Blepharoplasty / methods. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1967 Jun;39(6):619-24 [6026420.001]
  • [Cites] N Engl J Med. 1965 Oct 21;273(17):923-4 [5832875.001]
  • [Cites] J Surg Oncol. 1984 Feb;25(2):79-80 [6694405.001]
  • [Cites] J Surg Oncol. 1985 Jan;28(1):72-4 [3968892.001]
  • [Cites] J Am Acad Dermatol. 1986 Feb;14(2 Pt 1):186-96 [3950119.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] Ophthalmic Surg. 1993 Nov;24(11):755-8 [8290215.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] Plast Reconstr Surg. 1982 Jan;69(1):110-6 [7053498.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):631-6 [15051193.001]
  • [Cites] AORN J. 2000 Mar;71(3):552-4, 556-8, 560-4; quiz 565-70 [10736640.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Aug;78(4):430-6 [10990046.001]
  • [Cites] Br J Ophthalmol. 2001 Dec;85(12):1450-4 [11734520.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):257-63 [14871219.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):624-30 [15051192.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):926; author reply 926-7 [16782962.001]
  • [CommentIn] Br J Ophthalmol. 2006 May;90(5):660-1 [16622110.001]
  • (PMID = 16024851.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772767
  •  go-up   go-down


9. Blanchard E, Wierzbicka-Hainaut E, Thellier S, Dupeyron F, Guillet G: [Infiltrative basal cell carcinoma presenting as chronic leg ulcer]. Ann Dermatol Venereol; 2010 Mar;137(3):216-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infiltrative basal cell carcinoma presenting as chronic leg ulcer].
  • BACKGROUND: Basal cell carcinoma is the most common carcinoma of the skin and is usually found on the head and neck.
  • We report an unusual case of basal cell carcinoma presenting as a chronic leg ulcer, with underlying bone involvement.
  • Histological examination revealed infiltrative basal cell carcinoma.
  • Examination of the surgical piece revealed invasion of bone by the carcinoma.
  • DISCUSSION: There is a need for awareness among all doctors of the clinical signs evocative of malignant transformation of a leg ulcer so that a skin biopsy may be performed for suspicious ulcers.
  • Our case is distinguished by the underlying invasion of bone by basal cell carcinoma, as attested by imaging and histology.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Leg Ulcer / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Leg Bones / pathology. Leg Bones / surgery. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20227566.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Fukunaga M: Cutaneous spindle cell carcinoma following basal cell carcinoma. Am J Dermatopathol; 2005 Feb;27(1):17-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous spindle cell carcinoma following basal cell carcinoma.
  • A spindle cell carcinoma arose three years after the seeming excision of a so-called "infiltrative" basal cell carcinoma (IBCC) in the cheek of an 87-year-old Japanese woman.
  • The patient died after a local recurrence with metastatic lesions in the lung and the neck lymph nodes that were indicated by CT scanning and MRI at nine months after diagnosis.
  • This case and others support the concept that spindle cell carcinoma can pursue an aggressive clinical course.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basal Cell / pathology. Neoplasms, Second Primary. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2005 Dec;27(6):546; author reply 546 [16314711.001]
  • (PMID = 15677971.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


11. Potier A, Avenel Audran M, Belperron P, Briand E, Croue A, Verret JL: [Basal cell carcinoma of the first toenail]. Ann Dermatol Venereol; 2007 Oct;134(10 Pt 1):757-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell carcinoma of the first toenail].
  • BACKGROUND: Basal cell carcinoma is a very common form of skin cancer but its occurrence on the toenail unit is very rare.
  • We report such a case of basal cell carcinoma localized on the proximal nail fold of the right hallux.
  • Bowen's disease and squamous cell carcinoma were suspected.
  • Histopathologic examination of a biopsy specimen revealed infiltrative basal cell carcinoma.
  • DISCUSSION: Basal cell carcinoma is the most common skin cancer but its localization on fingers, toes and nail units is very rare.
  • Only six cases of basal cell carcinoma on the toe nail unit have been reported to date in the literature.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nail Diseases / pathology. Nails. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978714.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G: Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol; 2009 Aug;36(8):878-81
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
  • An 84-year-old male presented with recurrent nodular infiltrative basal cell carcinoma on the left shoulder.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy. Vitiligo / chemically induced. Vitiligo / pathology

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586497.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


13. Betti R, Menni S, Radaelli G, Bombonato C, Crosti C: Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol; 2010 Jul;37(7):611-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
  • Micronodular basal cell carcinoma (BCC) may be more difficult to eradicate and prone to recurrence than nodular subtype.
  • The aim of the study was to compare anatomical and histological characteristics of the basal cell carcinomas subtypes and the relationship of the micronodular BCC with other subtypes.
  • Primary BCCs (n = 3074) were classified as superficial, nodular, micronodular, morpheic/infiltrative.
  • Fifty-one micronodular BCCs were matched randomly with nodular and infiltrative cases, by age, sex, and tumor site.
  • Micronodular, nodular and infiltrative BCC were prevalently located in the head/neck (P < 0.0001), while superficial in the other regions (P < 0.0001).
  • The Clark level was comparable between micronodular and infiltrative BCC, while nodular BCC showed a more superficial level than micronodular (P < 0.001) and infiltrative (P < 0.001) BCC.
  • No nodular BCC had level IV and only 37.3% level III, while 92% of both micronodular and infiltrative BCC were level III or IV.
  • The percentage of level IV was 11.8% and 25.5% in micronodular and infiltrative BCC, respectively.
  • In the mid-face/periauricular region, 95.5% of micronodular and 100% of infiltrative cases of were level III or IV, compared to 50% of nodular BCC (P < 0.001).
  • It can be concluded that micronodular BCC shows intermediate characteristics compared with nodular and infiltrative subtypes but appears to have a specific individuality making it a distinct subtype.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Scalp / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629826.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Katona TM, Perkins SM, Billings SD: Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? J Cutan Pathol; 2008 Feb;35(2):174-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma?
  • BACKGROUND: Evaluation of androgen receptor (AR) and cytokeratin 20 (CK20) expression can aid in distinguishing between conventional basal cell carcinoma (characteristically AR+, CK20-) and trichoepithelioma (frequently AR-, CK20+).
  • Within these two groups of tumors, morpheaform/infiltrative basal cell carcinoma (mBCC) and desmoplastic trichoepithelioma (DTE) are particularly challenging to differentiate both clinically and histologically.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Keratin-20 / biosynthesis. Neoplasms, Basal Cell / metabolism. Receptors, Androgen / biosynthesis. Skin Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2009 Feb;36(2):283; author reply 284 [19208081.001]
  • [CommentIn] J Cutan Pathol. 2009 Oct;36(10):1121-2 [19522849.001]
  • (PMID = 18190441.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Receptors, Androgen
  •  go-up   go-down


15. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: [Cost analysis of Mohs micrographic surgery in high-risk facial basal cell carcinoma]. Actas Dermosifiliogr; 2010 Sep;101(7):622-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cost analysis of Mohs micrographic surgery in high-risk facial basal cell carcinoma].
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • Histology showed that 64% of the tumors were infiltrative or micronodular carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Carcinoma, Basal Cell / surgery. Facial Neoplasms / economics. Facial Neoplasms / surgery. Mohs Surgery / economics. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858388.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Monarca C, Chiummariello S, Mazzana P, Rizzo MI, Alfano C, Scuderi N: [Oncological and reconstructive management in a patient with multiple recurrences of basal cell carcinoma of the nose]. G Chir; 2008 Mar;29(3):89-91
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oncological and reconstructive management in a patient with multiple recurrences of basal cell carcinoma of the nose].
  • [Transliterated title] Management oncologico e ricostruttivo nella recidiva multipla del carcinoma basocellulare del naso.
  • Basal cell carcinoma (BCC) grows by direct extension replacing local anatomical structure; it rarely metastasizes, however may cause severe injure expanding to contiguous tissues with a biological invasive behaviour.
  • BCC of the nose is often a highly aggressive neoplasia with infiltrative growth pattern.
  • Therefore, he underwent surgical excision of the recurrence and the histological evaluation pointed out a metatypical and infiltrative BCC pattern without margins involvement.
  • Histological examination still demonstrated a metatypical and infiltrative pattern, with disease free margins, but nasal vestibule involvement.
  • Histological evaluation demonstrated a metatypical solid infiltrative BCC pattern with disease free margins and lymph nodes.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Nose Neoplasms / surgery
  • [MeSH-minor] Aged. Cheek / pathology. Cheek / surgery. Disease-Free Survival. Facial Neoplasms / pathology. Facial Neoplasms / surgery. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness / pathology. Nose / pathology. Reconstructive Surgical Procedures. Surgical Flaps. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Basal Cell Carcinoma, Multiple.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366887.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Merritt BG, Snow SN, Longley BJ: Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis; 2010 May;85(5):254-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
  • Desmoplastic trichoepithelioma (DTE), infiltrative/morpheaform basal cell carcinoma (BCC), and microcystic adnexal carcinoma (MAC) are tumors in this category that may be difficult to differentiate, especially when evaluating thin biopsy specimens.
  • An accurate diagnosis has important clinical implications.
  • While DTE is a benign neoplasm with indolent behavior, infiltrative/morpheaform BCC and MAC can be highly aggressive, leading to substantial local destruction and potential metastasis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Skin Appendage / pathology. Mohs Surgery. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-20. Male. Middle Aged. Staining and Labeling

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540416.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20
  •  go-up   go-down


18. Piesold JU, Vent S, Krüger R, Pistner H: [Treatment results after surgery for basal cell carcinomas of the head and neck region taking into consideration various reconstruction techniques]. Mund Kiefer Gesichtschir; 2005 May;9(3):143-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results after surgery for basal cell carcinomas of the head and neck region taking into consideration various reconstruction techniques].
  • BACKGROUND: Basal cell carcinomas are the most frequently occurring malignant tumors in the white population.
  • PATIENTS AND METHOD: All cases of basal cell carcinoma treated at the department for oral and maxillofacial and regional plastic surgery of the HELIOS hospital in Erfurt between 1976 and 2003 were analyzed and partly reexamined in a retrospective study.
  • RESULTS: A total of 648 patients with 765 basal cell carcinomas were treated.
  • In 64% of the cases the basal cell carcinomas were nodular, in 16% infiltrative.
  • DISCUSSION: If an infiltrative basal cell carcinoma is suspected or insufficient radical primary surgery is presumed, plastic reconstruction should be postponed until free margins can be confirmed histologically.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasms, Radiation-Induced / surgery. Skin Neoplasms / surgery. Sunlight / adverse effects
  • [MeSH-minor] Aged. Dermatologic Surgical Procedures. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Orbit Evisceration. Outcome and Process Assessment (Health Care). Retrospective Studies. Skin / pathology. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] J Am Acad Dermatol. 1992 Jan;26(1):117-20 [1732317.001]
  • [Cites] Aust J Public Health. 1994 Jun;18(2):218-21 [7948343.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:50-2 [14616351.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1200-6 [14674897.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1221-6 [14674900.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:57-8 [14616353.001]
  • (PMID = 15719264.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Chuprov IN: [Immunomorphological features of cutaneous basal-cell carcinoma]. Vopr Onkol; 2008;54(6):715-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunomorphological features of cutaneous basal-cell carcinoma].
  • An immunohistochemical study of p53, Ki-67, bcl-2, CK-8 and collagen IV was conducted in 47 basal-cell carcinomas (BCC) to ascertain their prognostic value.
  • The increasing index of the proliferative markers (Ki-67 up to 55.71 and p53 up to 63.29%, respectively) was characteristic of infiltrative BCC (p = 0.017-0.027).
  • High anti-apoptotic bcl-2 expression in superficial BCC (36.85%) was matched by its decrease in nodular carcinoma and was minimal in high grade infiltrative BCC (13.24%).
  • Most prominent basement membrane ruptures, as evaluated by collagen IV expression, occurred in infiltrative BCC (p=0.008).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Skin Neoplasms / chemistry. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Basement Membrane / chemistry. Basement Membrane / pathology. Collagen Type IV / analysis. Female. Humans. Immunohistochemistry. Keratin-8 / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241845.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


20. Leibovitch I, McNab A, Sullivan T, Davis G, Selva D: Orbital invasion by periocular basal cell carcinoma. Ophthalmology; 2005 Apr;112(4):717-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion by periocular basal cell carcinoma.
  • OBJECTIVES: To present a large series of patients with orbital invasion by periocular basal cell carcinoma (BCC).
  • Most patients (51.6%) had infiltrative histologic findings, and perineural invasion was present in 19.3%.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Peripheral Nervous System Neoplasms / radiotherapy. Peripheral Nervous System Neoplasms / secondary. Peripheral Nervous System Neoplasms / surgery. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808267.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


21. Allali J, D'Hermies F, Renard G: Basal cell carcinomas of the eyelids. Ophthalmologica; 2005 Mar-Apr;219(2):57-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas of the eyelids.
  • Basal cell carcinomas (BCC) are the more frequent malignant tumors seen in France as in other western countries.
  • Recurrences are more aggressive, infiltrative and destructive and have a considerably poorer rate of cure than primary tumors.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Incidence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15802929.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 141
  •  go-up   go-down


22. Agero AL, Busam KJ, Benvenuto-Andrade C, Scope A, Gill M, Marghoob AA, González S, Halpern AC: Reflectance confocal microscopy of pigmented basal cell carcinoma. J Am Acad Dermatol; 2006 Apr;54(4):638-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reflectance confocal microscopy of pigmented basal cell carcinoma.
  • OBJECTIVE: We sought to describe the relevant RCM features for pigmented basal cell carcinoma (BCC).
  • METHODS: Pigmented skin lesions with a differential diagnosis of pigmented BCC were imaged using dermoscopy and RCM, followed by excision for histologic analysis.
  • LIMITATIONS: The pigmented BCCs imaged in this study were predominantly nodular; a different set or additional criteria may be necessary for detection of infiltrative and metatypical BCCs.
  • CONCLUSION: RCM may permit in vivo diagnosis of pigmented BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Melanoma / diagnosis. Melanoma / pathology. Microscopy, Confocal. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546585.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Gambichler T, Orlikov A, Vasa R, Moussa G, Hoffmann K, Stücker M, Altmeyer P, Bechara FG: In vivo optical coherence tomography of basal cell carcinoma. J Dermatol Sci; 2007 Mar;45(3):167-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo optical coherence tomography of basal cell carcinoma.
  • BACKGROUND: Optical coherence tomography (OCT) is a promising non-invasive imaging technique that has not systematically been studied in skin cancer such as basal cell carcinoma (BCC).
  • With regard to the aforementioned OCT features, no statistically significant (P<0.05) difference was found between nodular, multifocal superficial, and infiltrative BCCs, respectively.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Tomography, Optical Coherence
  • [MeSH-minor] Aged. Dermis / pathology. Diagnosis, Differential. Epidermis / pathology. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215110.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Raasch BA, Buettner PG, Garbe C: Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol; 2006 Aug;155(2):401-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: histological classification and body-site distribution.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer worldwide in white-skinned populations.
  • Incidence rates for 'high risk' BCC were 261.3 for males, 146.5 for females with infiltrative, and 156.7 for males and 100.2 for females with micronodular types.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882181.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Tuttle MS, Rosenberg AS, Winfield HL, Somach SC: Pseudocarcinomatous hyperplasia with follicular differentiation overlying basal cell carcinoma. Am J Dermatopathol; 2009 Aug;31(6):557-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudocarcinomatous hyperplasia with follicular differentiation overlying basal cell carcinoma.
  • We present a series of 25 cases of basal cell carcinoma (BCC) with overlying cytologically bland epidermal hyperplasia and cyst formation.
  • Eight of the BCCs were nodular and 11 were infiltrative.
  • In the majority of cases, Ki-67 expression was prominent throughout the BCCs, but only expressed in the basal and suprabasal layers of the adjacent hyperplastic epithelium, which was equivalent to normal epidermis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Differentiation. Cysts / metabolism. Cysts / pathology. Female. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2011 Feb;33(1):107 [21239900.001]
  • (PMID = 19590419.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Slodkowska EA, Cribier B, Peltre B, Jones DM, Carlson JA: Calcifications associated with basal cell carcinoma: prevalence, characteristics, and correlations. Am J Dermatopathol; 2010 Aug;32(6):557-64
Hazardous Substances Data Bank. CALCIUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifications associated with basal cell carcinoma: prevalence, characteristics, and correlations.
  • BACKGROUND: Carcinoma-associated calcifications (Ca(2+)) are a common phenomenon.
  • In the skin, basal cell carcinomas (BCC) can be associated with Ca(2+).
  • Comparing all BCC, high-risk BCC (mostly infiltrative) had significantly higher frequency of Ca(2+) than low-risk (mostly nodular) BCC (44% vs. 25%; P = 0.009).
  • [MeSH-major] Calcinosis / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489568.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium Compounds
  •  go-up   go-down


27. Tanori M, Mancuso M, Pasquali E, Leonardi S, Rebessi S, Di Majo V, Guilly MN, Giangaspero F, Covelli V, Pazzaglia S, Saran A: PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma. Carcinogenesis; 2008 Oct;29(10):1911-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
  • The patched (Ptc1) protein is a negative regulator of sonic hedgehog signaling, a genetic pathway whose perturbation causes developmental defects and predisposition to specific malignant tumors.
  • Humans and mice with mutated Ptc1 are prone to medulloblastoma and basal cell carcinoma (BCC), both tumors showing dependence on radiation damage for rapid onset and high penetrance.
  • In addition to increased formation and slowed down kinetics of disappearance of gamma-H2AX foci, we observed increased apoptosis in PARP-1-deficient granule cell progenitors after irradiation.
  • Double-mutant mice were also strikingly more susceptible to BCC, with >50% of animals developing multiple, large, infiltrative tumors within 30 weeks of age.
  • [MeSH-major] Carcinoma, Basal Cell / prevention & control. Medulloblastoma / prevention & control. Poly(ADP-ribose) Polymerases / physiology. Receptors, Cell Surface / physiology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18660545.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histones; 0 / Receptors, Cell Surface; 0 / gamma-H2AX protein, mouse; 0 / patched receptors; EC 2.4.2.30 / Parp1 protein, mouse; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


28. Ly E, Durlach A, Antonicelli F, Bernard P, Manfait M, Piot O: Probing tumor and peritumoral tissues in superficial and nodular basal cell carcinoma using polarized Raman microspectroscopy. Exp Dermatol; 2010 Jan;19(1):68-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing tumor and peritumoral tissues in superficial and nodular basal cell carcinoma using polarized Raman microspectroscopy.
  • Basal cell carcinoma (BCC) can sometimes lead, through a possible invasion of the dermis and the subcutaneous tissue, to serious local damage to the patient.
  • Several histological types of BCC are reported, among them, the superficial, nodular and infiltrative forms.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Skin Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845756.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


29. Simeonov R, Simeonova G: Nucleomorphometric analysis of feline basal cell carcinomas. Res Vet Sci; 2008 Jun;84(3):440-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleomorphometric analysis of feline basal cell carcinomas.
  • Twenty-four feline spontaneous basal cell carcinomas (BCCs) were analyzed by computerized nuclear morphometry.
  • The analysis of data of the non-recurrent BCCs and the recurrent tumours revealed statistically significant differences between those groups (p<0.001) as well as between infiltrative and clear types of BCCs (p<0.05).
  • [MeSH-major] Carcinoma, Basal Cell / veterinary. Cat Diseases / pathology. Cell Nucleus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706734.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Misago N, Mori T, Narisawa Y: Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Nov;24(11):1354-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma.
  • BACKGROUND: Both trichoblastoma and basal cell carcinoma (BCC) are considered to be a benign and malignant neoplasm of follicular germinative cells respectively.
  • METHODS: Immunohistochemical staining was performed with antibody against nestin for 15 trichoblastomas including large/small nodular, retiform and trichoepithelioma types, while adding the superficial type associated with nevus sebaceous and for 20 BCCs including superficial, nodular, nodulo-infiltrative, and infiltrative/micronodular types.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Sebaceous Gland Neoplasms / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337823.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


31. Ansarin H, Daliri M, Soltani-Arabshahi R: Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol; 2006 Sep-Oct;16(5):543-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
  • Basal cell carcinoma (BCC) generally has an indolent course but a subgroup of BCCs tends to grow aggressively into deep tissues and even metastasize.
  • Tumors were categorized as aggressive (infiltrative or morpheic) and non-aggressive (nodular or superficial) based on histopathological examination of hematoxylin and eosin sections. p53 expression was demonstrated by immunohistochemical staining using the monoclonal anti-p53 antibody (PAb240) and results were reported using a semiquantitative score.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Basal Cell / genetics. Skin Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101476.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


32. Figueroa A, Correnti M, Avila M, Andea A, DeVilliers P, Rivera H: Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type? Otolaryngol Head Neck Surg; 2010 Feb;142(2):179-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type?
  • OBJECTIVE: The objective of this study was to analyze the expression of proliferative markers and p53 in keratocystic odontogenic tumor (KCOT) sporadic type and KCOT associated with nevoid basal cell carcinoma syndrome (NBCCS).
  • Immunohistochemical analysis for p53, proliferating cell nuclear antigen (PCNA), and Ki-67 was performed in all 19 cases.
  • CONCLUSION: On the basis of the analysis of the expression of PCNA, Ki-67, and p53, there appears to be no evidence to indicate higher aggressiveness in growth and infiltrative behavior in syndromic KCOT compared with the sporadic type.
  • [MeSH-major] Basal Cell Nevus Syndrome / metabolism. Basal Cell Nevus Syndrome / pathology. Biomarkers, Tumor / analysis. Odontogenic Cysts / metabolism. Odontogenic Cysts / pathology
  • [MeSH-minor] Cross-Sectional Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115971.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


33. Garcia C, Poletti E, Crowson AN: Basosquamous carcinoma. J Am Acad Dermatol; 2009 Jan;60(1):137-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma.
  • BACKGROUND: Basosquamous carcinoma is considered an aggressive type of basal cell carcinoma (BCC) with an increased risk of recurrence and metastases.
  • METHODS: This is a narrative review based on a MEDLINE search of articles in English and a manual search of popular dermatology textbooks to define basosquamous carcinoma, its incidence, clinical behavior, and treatment of choice.
  • RESULTS: There are no specific clinical features to distinguish basosquamous carcinoma from other BCC types and the diagnosis is made only after biopsy.
  • There are several histologic definitions of basosquamous carcinoma ranging from a characteristic combination of BCC and squamous cell carcinoma with or without a transition zone, to any BCC with evidence of keratinization.
  • The authors confine the use of the term to an infiltrative growth BCC with areas of keratinization and/or intercellular bridge formation in the setting of a prototypic proliferative stromal reaction.
  • The term "metatypical basal cell carcinoma" is considered a synonym but its use is discouraged for the reasons outlined.
  • The reported incidence of basosquamous carcinoma ranges from 1.2% to 2.7%.
  • The aggressive biological behavior and clinical course distinguish basosquamous carcinoma from other forms of BCC.
  • CONCLUSION: The terminology surrounding basosquamous carcinoma is confusing and there is a need for more uniform language.
  • Data regarding the incidence, recurrence, and metastasis rates of basosquamous carcinoma are based mostly on retrospective series with a limited number of cases.
  • We conclude that although the incidence of basosquamous carcinoma is unknown, there is a literature precedent suggesting more aggressive biological behavior.
  • We believe that complete surgical excision is the preferred approach, and that basosquamous carcinoma is an ideal candidate lesion for Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basosquamous. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103364.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


34. Farhi D, Dupin N, Palangié A, Carlotti A, Avril MF: Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg; 2007 Oct;33(10):1207-14
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases.
  • BACKGROUND: Reported rates of incomplete excision of basal cell carcinoma (BCC) range from 4% to 16.6%.
  • In the multivariate analysis, incomplete excision was independently associated with location on the nasal ala (p<.02), other parts of the nose (p=.02), and inner canthus (p=.01) and with infiltrative (p<.0001) and multifocal (p<.0001) types.
  • CONCLUSION: Pathologically reported incomplete excision rate was comparable to that of other studies and was significantly associated with the location on the face, particularly on the nose and inner canthus, and with infiltrative and multifocal histologic types.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Outcome Assessment (Health Care). Skin Neoplasms / surgery. Surgical Procedures, Operative / standards

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903153.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


35. Papanikolaou S, Bravou V, Gyftopoulos K, Nakas D, Repanti M, Papadaki H: ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion. Histopathology; 2010 May;56(6):799-809
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion.
  • The aim was to study ILK expression and its relevance to EMT markers in human basal cell carcinoma (BCC).
  • ILK overexpression was observed in 100% of cases and strongly correlated with tumour invasion and infiltrative BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Epithelial Cells / metabolism. Mesenchymal Stromal Cells / metabolism. Protein-Serine-Threonine Kinases / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cadherins / metabolism. Humans. Immunohistochemistry. Neoplasm Invasiveness. Transcription Factors / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546345.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Transcription Factors; 0 / beta Catenin; 0 / snail family transcription factors; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


36. Gore SM, Kasper M, Williams T, Regl G, Aberger F, Cerio R, Neill GW, Philpott MP: Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation? J Pathol; 2009 Sep;219(1):61-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation?
  • Although deregulated Hedgehog signalling and elevated Gli transcription factor expression are known to promote the development of basal cell carcinoma (BCC), little is known about molecular mechanisms driving the development of specific growth pattern subtypes.
  • Moreover, we found that expression of these neuronal differentiation markers showed strong correlation to BCC subtype, with more aggressive infiltrative and morphoeic BCC showing low levels or lack of expression compared to nodular, superficial and micronodular subtypes.
  • Moreover, we suggest that correlation between loss of expression of neuronal markers in infiltrative and morphoeic BCC subtypes reflects dedifferentiation of more aggressive BCC subtypes.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Gene Expression Regulation, Neoplastic. Hedgehog Proteins / genetics. Neurons / pathology
  • [MeSH-minor] Analysis of Variance. Biomarkers / analysis. Case-Control Studies. Cell Differentiation. Cells, Cultured. Cytoskeletal Proteins / genetics. GAP-43 Protein / genetics. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Keratinocytes / metabolism. Kruppel-Like Transcription Factors / genetics. Nerve Tissue Proteins / genetics. Neurofilament Proteins / genetics. Neuronal Plasticity. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction / physiology. Transcription Factors / genetics. Transduction, Genetic. Tubulin / genetics. Zinc Finger Protein GLI1

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479712.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 20652; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytoskeletal Proteins; 0 / GAP-43 Protein; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tubulin; 0 / Zinc Finger Protein GLI1; 0 / activity regulated cytoskeletal-associated protein
  •  go-up   go-down


37. Madge SN, Khine AA, Thaller VT, Davis G, Malhotra R, McNab A, O'Donnell B, Selva D: Globe-sparing surgery for medial canthal Basal cell carcinoma with anterior orbital invasion. Ophthalmology; 2010 Nov;117(11):2222-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Globe-sparing surgery for medial canthal Basal cell carcinoma with anterior orbital invasion.
  • PURPOSE: To describe a case series of patients with anterior orbital invasion by medial canthal basal cell carcinoma (BCC) managed with non-exenterating surgery.
  • Histologic evidence of orbital invasion was present in every patient, the subtypes being infiltrative (9/20, 45%), nodular (4/20, 20%), micronodular (2/20, 10%), multifocal (1/20, 5%), and mixed (4/20, 20%); extratumoral perineural invasion was present in 1 patient (5%).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Neoplasm Recurrence, Local. Ophthalmologic Surgical Procedures. Orbit / surgery. Orbital Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20570356.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Wagoner J, Keehn C, Morgan MB: CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma. Am J Dermatopathol; 2007 Dec;29(6):555-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma.
  • Basal cell carcinoma and squamous cell carcinoma are common entities in clinical practice.
  • We sought to determine if the CD10 immunostain could have diagnostic utility in distinguishing between early superficial basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • CD10 was strongly expressed in 14 out of 14 superficial BCCs and failed to express in 2 out of 2 deeply infiltrative BCCs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neprilysin / analysis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032951.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


39. Su SY, Giorlando F, Ek EW, Dieu T: Incomplete excision of basal cell carcinoma: a prospective trial. Plast Reconstr Surg; 2007 Oct;120(5):1240-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: a prospective trial.
  • Reported rates of incomplete excision of basal cell carcinoma vary widely (5 to 25 percent) among centers worldwide.
  • METHODS: From January of 2001 to December of 2002, 1214 basal cell carcinomas were excised at Peter MacCallum Cancer Centre.
  • Risk factors for incomplete excision are the head site; morpheic, superficial, and infiltrative subtypes; lesions larger than 20 mm in diameter; the presence of multiple lesions; repair by skin graft; and recurrent and previously incompletely excised basal cell carcinomas.
  • CONCLUSIONS: This is the largest prospective study of incomplete excision of basal cell carcinomas.
  • Preoperative "red-flagging" of basal cell carcinomas most at risk of incomplete excision may lead to a better result.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898596.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Fernández-Vozmediano JM, Armario-Hita JC: Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b. J Drugs Dermatol; 2010 Apr;9(4):381-4
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.
  • For patients with basal cell carcinoma (BCC) in whom surgical intervention is not optimal, local treatment with interferon alfa-2b is an alternative.
  • Twelve patients, primarily with the infiltrative histologic form (80%), were treated.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Interferon-alpha / administration & dosage. Nose Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514797.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


41. Parwani AV, Smith Sehdev AE, Kurman RJ, Ronnett BM: Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: clinicopathologic features, human papillomavirus DNA detection, and P16 expression. Hum Pathol; 2005 Jan;36(1):82-90
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: clinicopathologic features, human papillomavirus DNA detection, and P16 expression.
  • Adenoid basal tumors are uncommon cervical lesions that some pathologists consider invasive carcinomas but others consider "epitheliomas" due to their low-grade histological appearance and rarely documented malignant behavior.
  • We report the clinicopathologic features of 10 tumors comprised of both typical low-grade adenoid basal tumors (epitheliomas) intimately associated with invasive carcinomas having infiltrative growth, increased cytological atypia and mitotic activity, and various types of differentiation, including adenoid basal/squamous, pure squamous, adenoid cystic, and small cell neuroendocrine.
  • The initial diagnosis was made on specimens obtained by cervical biopsy, laser electrocautery excision procedure (LEEP), or cone biopsy in 8 patients.
  • In all cases diagnosed in LEEP or cone biopsy specimens, the invasive carcinoma component was present in the excisional specimen and extended to the margins.
  • One patient with a component of small cell carcinoma died of other causes without evidence of disease at 18 months.
  • HPV 16 DNA was detected in both the adenoid basal epithelioma and invasive carcinoma components in 9 tumors by in situ hybridization, and HPV 33 was detected by polymerase chain reaction in 1 tumor.
  • Adenoid basal tumors are high-risk HPV-related tumors that can be comprised of both a low-grade adenoid basal tumor, which can be designated as epithelioma, and invasive carcinomas of various types.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Viral / isolation & purification. Uterine Cervical Neoplasms / classification. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15712186.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


42. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Other diagnostic considerations include adenoid cystic carcinoma and basaloid squamous carcinoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • Radiotherapy has been proposed for lesions in the minor salivary glands because of the higher likelihood of vascular and neural invasion and for those that are diffusely infiltrative.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Kaur P, Mulvaney M, Carlson JA: Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol; 2006 Aug;28(4):293-307

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis.
  • Basal cell carcinoma (BCC) can be subclassified into low- and high-risk types for local recurrence.
  • Nodular (84%) was the most common pattern identified followed by superficial (77%), infiltrative (27%), morpheic (5%) and micronodular patterns (4%).
  • Micronodular and infiltrative-morpheic patterns were not identified together in mixed patterned BCCs, and these high-risk types were contiguous with nodular BCC.
  • Significant correlations were identified for BCC subtypes with inflammatory and stromal alterations: superficial BCC with old regression and moderate to dense peritumoral lymphocytic infiltrates; high-risk types correlated with active regression; infiltrative and morpheic BCC with fibrosing tumor stroma; and micronodular BCC with loss of both host inflammatory and stromal tumor responses.
  • Evaluating the theoretical histologic stepwise model of BCC progression (superficial-to-nodular-to-micronodular, or superficial-to-nodular-to-infiltrative-to-morpheic BCC types) revealed significant linear correlations with host response and alterations of tumor stroma (r=0.54, P=0.0001).
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Carcinoma, Basal Cell / pathology. Stromal Cells / immunology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Shape. Disease Progression. Female. Humans. Inflammation / immunology. Inflammation / pathology. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871032.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Ali TZ, Epstein JI: Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2007 May;31(5):697-705
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases.
  • We studied 29 cases of basal cell carcinoma of the prostate including what others call adenoid cystic carcinoma of the prostate.
  • The most common methods of diagnosis was transurethral resection (TURP) (n=29) and needle biopsy (n=9).
  • Other patterns included: basal cell hyperplasialike in 9 cases (32%); small tubules occasionally lined by a hyaline rim in 9 cases (32%), with 4 of these cases also demonstrating intermingling cords of cells; and large solid nests in 8 cases (28.5%), 5 of which had central necrosis.
  • Perineural and vascular invasion was seen in 2 basal cell carcinomas with large basaloid nests.
  • Basal cell markers (HMWCK, p63) either:.
  • Basal cell carcinomas are rare tumors with a broad morphologic spectrum.
  • These tumors predominantly show an indolent course with local infiltrative behavior.
  • The most common morphology among those with an aggressive behavior is large solid nests more often with central necrosis, high Ki67%, and less staining with basal cell markers.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Combined Modality Therapy. Humans. Male. Middle Aged. Mitosis. Neoplasm Recurrence, Local. Retrospective Studies. Transurethral Resection of Prostate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460452.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Mc Menamin ME, Goh SG, Poblet E, Gostelow BE, Robson A, Calonje E: Sarcomatoid basal cell carcinoma--predilection for osteosarcomatous differentiation: a series of 11 cases. Am J Surg Pathol; 2006 Oct;30(10):1299-308
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid basal cell carcinoma--predilection for osteosarcomatous differentiation: a series of 11 cases.
  • Primary cutaneous carcinomas rarely show heterologous malignant mesenchymal differentiation.
  • We report 11 cases of sarcomatoid basal cell carcinoma (BCC) with osteosarcomatous differentiation.
  • Ten tumors were well-circumscribed and 1 tumor showed focally infiltrative edges.
  • One case showed a purely osteoclastic giant cell rich malignant mesenchyme, interpreted as representing early stages of osteosarcomatous transformation.
  • Previously unreported in sarcomatoid BCC, the mesenchymal component of another two cases displayed predominant malignant giant cell tumor like areas and 1 further case disclosed areas reminiscent of telangiectatic osteosarcoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinosarcoma / pathology. Cell Transformation, Neoplastic / pathology. Osteosarcoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001162.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


46. Mavrikakis I, Malhotra R, Barlow R, Huilgol SC, Selva D: Linear basal cell carcinoma: a distinct clinical entity in the periocular region. Ophthalmology; 2006 Feb;113(2):338-42
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear basal cell carcinoma: a distinct clinical entity in the periocular region.
  • PURPOSE: To report periocular linear basal cell carcinoma (BCC) as a distinct clinical entity, and to highlight its existence in the ophthalmic literature.
  • Histology revealed pigmented nodular BCC with an infiltrative component in 2 cases and nodular BCC in the remaining 2 cases.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406534.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


47. Østergaard J, Boberg-Ans J, Prause JU, Heegaard S: Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):615-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.
  • BACKGROUND: To report the clinical and histopathological characteristics of a patient with a primary basal cell carcinoma (BCC) of the caruncle with seeding of the tumour to the conjunctiva.
  • Microscopically, both neoplasms were composed of infiltrative islands of basaloid tumour cells, scattered mitoses and peripheral palisading consistent with the diagnosis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Conjunctival Neoplasms / secondary. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 1993 Sep-Oct;38(2):169-92 [8235999.001]
  • [Cites] Arch Ophthalmol. 1998 Oct;116(10):1373-4 [9790642.001]
  • [Cites] Arch Ophthalmol. 2000 Sep;118(9):1296-8 [10980780.001]
  • [Cites] Br J Ophthalmol. 1973 Nov;57(11):836-7 [4785248.001]
  • [Cites] Am J Ophthalmol. 1982 Nov;94(5):591-3 [7148940.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • [Cites] Cornea. 1987;6(2):78-116 [3301209.001]
  • [Cites] Indian J Ophthalmol. 1975 Oct;23(3):33-4 [1236314.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Oct;78(5):547-52 [11037913.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1585-7 [9400796.001]
  • (PMID = 15614536.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, Joos S: Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep; 2006 May;15(5):1141-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
  • Formation of basal cell carcinoma (BCC) has been linked to deregulation in the sonic hedgehogh (Shh) signalling pathway.
  • Strong Nmyc immunopositivity was more frequently found in infiltrative BCCs compared to nodular/superficial BCCs (p=0.005), and in BCCs of the head compared to BCCs of other anatomic localisations (p=0.021).
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Dosage. Genes, myc / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596176.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


49. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol; 2009 Dec;145(12):1431-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
  • OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC.
  • Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC, 42% to 100% for nodular BCC, 56% to 63% for infiltrative BCC, 73% to 88% for SCC in situ, and 71% for invasive SCC.
  • [MeSH-major] Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / pharmacokinetics. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026854.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 47
  •  go-up   go-down


50. Koseoglu RD, Sezer E, Eyibilen A, Aladag I, Etikan I: Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas. J Cutan Pathol; 2009 Sep;36(9):958-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas.
  • BACKGROUND: We planned this study to analyze probable associations between p53, cyclinD1, Ki67 and histopathological features in basal cell carcinomas (BCC).
  • Solid infiltrative type differentiation was related to the infiltrative histological growth pattern.
  • The rates of p53 positivity and severe fibrosis in the groups of mixed and infiltrative growth patterns were higher than others.
  • CONCLUSIONS: P53 expression seems to be related to Ki67 index and some histopathological features of BCC, such as infiltrative histological growth pattern and probably fibrosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cyclin D1 / biosynthesis. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187116.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


51. Olmedo JM, Warschaw KE, Schmitt JM, Swanson DL: Optical coherence tomography for the characterization of basal cell carcinoma in vivo: a pilot study. J Am Acad Dermatol; 2006 Sep;55(3):408-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical coherence tomography for the characterization of basal cell carcinoma in vivo: a pilot study.
  • OBJECTIVE: The purpose of this pilot study was to define and characterize basal cell carcinoma by using optical coherence tomography.
  • METHODS: Twenty-three patients with 49 lesions clinically suggestive of superficial basal cell carcinoma were recruited.
  • RESULTS: Basal cell carcinoma was identified in 27 patients; all 27 had optical coherence tomographic images for comparison.
  • Of the remainder, 20 sites matched the histologic features seen on light microscopy, with excellent correlation between optical coherence tomographic images and histopathologic features of superficial, nodular, micronodular and infiltrative basal cell carcinomas.
  • CONCLUSIONS: Optical coherence tomography technology has potential for the diagnosis and histopathologic characterization of basal cell cancer.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Tomography, Optical Coherence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908344.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Betti R, Radaelli G, Bombonato C, Crosti C, Cerri A, Menni S: Anatomic location of Basal cell carcinomas may favor certain histologic subtypes. J Cutan Med Surg; 2010 Nov-Dec;14(6):298-302
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic location of Basal cell carcinomas may favor certain histologic subtypes.
  • BACKGROUND: Differences in age, site, and subtype exist in basal cell carcinoma (BCC).
  • Subtype was classified as superficial, nodular, micronodular, morpheic-infiltrative, or fibroepithelial.
  • The prevalence of nodular or morpheic/infiltrative subtype was higher among BCCs on the head/neck than other locations, that is, 57.1% versus 29.2%, OR 3.23, 95% CI 2.79 to 3.74 (nodular) and 16.1% versus 4.0%, OR 4.56, 95% CI 3.42 to 6.08 (morpheic/infiltrative).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084023.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Aiad HA, Hanout HM: Immunohistochemical Expression of CD10 in Cutaneous Basal and Squamous Cell Carcinomas. J Egypt Natl Canc Inst; 2007 Sep;19(3):195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical Expression of CD10 in Cutaneous Basal and Squamous Cell Carcinomas.
  • We aimed to determine the immunohistochemical expression of CD10 in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) and to associate it with the available clinicopathological parameters in both tumors.
  • Patients and Methods : This study included 16 SCC and 21 BCC cases (17 solid type, 2 morphea type and 2 adenoid basal types).
  • BCC cases were divided into 12 cases with microscopic infiltrative base and 9 cases with well-circumscribed base.
  • Results : Positive CD10 staining was identified as brown cytoplasmic, with or without cell membrane staining.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190692.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


54. Patel YG, Nehal KS, Aranda I, Li Y, Halpern AC, Rajadhyaksha M: Confocal reflectance mosaicing of basal cell carcinomas in Mohs surgical skin excisions. J Biomed Opt; 2007 May-Jun;12(3):034027
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal reflectance mosaicing of basal cell carcinomas in Mohs surgical skin excisions.
  • Precise removal of basal cell carcinomas (BCCs) with minimal damage to the surrounding normal skin is guided by the examination of frozen histology of each excision during Mohs surgery.
  • However, infiltrative and sclerosing BCCs tend to be obscured within the surrounding bright dermis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Image Interpretation, Computer-Assisted / methods. Microscopy, Confocal / methods. Mohs Surgery / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Surgery, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614735.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01EB002715
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


55. Soysal HG, Soysal E, Markoç F, Ardiç F: Basal cell carcinoma of the eyelids and periorbital region in a Turkish population. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):201-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids and periorbital region in a Turkish population.
  • PURPOSE: To review the clinical and histopathologic features, treatment, and outcomes of eyelid basal cell carcinomas.
  • METHODS: The clinical records and histopathologic specimens of 311 patients with eyelid basal cell carcinomas were reviewed and analyzed retrospectively.
  • The most common histologic subtypes were infiltrative, nodular, and basosquamous basal cell carcinomas.
  • Recurrent basal cell carcinomas were larger, with longer duration of lesion and a higher rate of orbital and perineural invasion.
  • Basosquamous basal cell carcinomas were more likely to have prior recurrences, larger lesion size, and the highest rate of orbital invasion.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520835.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. McCutcheon B, White K, Kotwall C, Germolic D, Rebolloso Y, Hamann MS, Stiles A: A preliminary study of imiquimod treatment in variants of basal cell carcinoma. Am Surg; 2005 Aug;71(8):662-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary study of imiquimod treatment in variants of basal cell carcinoma.
  • Imiquimod is a topical immune response modifier that has proved efficacious in the treatment of the superficial variant of basal cell carcinoma.
  • The nodular variant of basal cell carcinoma has shown moderate response to imiquimod; other variants have not been tested.
  • The objective of this study is to evaluate the cytokine response of imiquimod in all variants of basal cell carcinoma.
  • Ten patients were selected who had clinically and histologically proven basal cell carcinoma.
  • Nine of 10 lesions resolved clinically, which included nodular, superficial, infiltrative, adenoid, and micronodular variants.
  • We concluded that topical 5 per cent imiquimod is an effective treatment of various subtypes of basal cell carcinoma.
  • Larger studies are needed to prove the efficacy of imiquimod on nonsuperficial variants of basal cell carcinoma and cutaneous melanoma metastasis.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217949.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


57. Svensson Månsson S, Reis-Filho J, Landberg G: Transcriptional upregulation and unmethylation of the promoter region of p16 in invasive basal cell carcinoma cells and partial co-localization with the gamma 2 chain of laminin-332. J Pathol; 2007 May;212(1):102-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional upregulation and unmethylation of the promoter region of p16 in invasive basal cell carcinoma cells and partial co-localization with the gamma 2 chain of laminin-332.
  • Basal cell carcinoma cells show low proliferation rates at the invasive front and a concordant upregulation of the cdk-inhibitor p16, limiting proliferative capacity.
  • Little is known about the mechanisms of p16 regulation in normal and malignant cells apart from that many transcription factors such as Ets1, Ets2, SP1, SP3, JunB and the polycomb protein Bmi1 have the potential to induce or repress p16 expression.
  • Therefore, the aim of this study was to determine how p16 is regulated in basal cell carcinoma with special focus on its upregulation in invasive cells.
  • By analysing various microdissected areas of basal cell carcinoma using real-time quantitative PCR we observed upregulation of p16 mRNA in invasive tumour cells compared to centrally localized tumour cells.
  • Interestingly, in basal cell carcinoma we observed partial co-localization between p16 and the gamma 2 chain of laminin-332 in tumour cells towards areas of ulceration and in the majority of clearly infiltrative tumour cells but not in p16 positive tumour cells with a more pushing invasive growth pattern.
  • These data suggest that concurrent p16 upregulation and decreased proliferation are more general phenomena in different types of invasive growth patterns in basal cell carcinomas and that these only partially overlap with the gamma 2 chain of laminin-332 associated invasion patterns.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / genetics. Gene Expression Regulation, Neoplastic. Genes, p16. Laminin / analysis. Promoter Regions, Genetic
  • [MeSH-minor] Blotting, Western. Cell Adhesion Molecules / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA Methylation. Humans. Immunohistochemistry. Neoplasm Invasiveness. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17370299.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Laminin; 0 / RNA, Messenger; 0 / kalinin
  •  go-up   go-down


58. Jambusaria-Pahlajani A, Schmults CD, Miller CJ, Shin D, Williams J, Kurd SK, Gelfand JM: Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery. Dermatol Surg; 2009 Jan;35(1):9-15; discussion 15-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery.
  • OBJECTIVES: To determine the accuracy of high-resolution ultrasound to assess the margins of basal cell (BCC) and squamous cell carcinomas (SCC) before Mohs micrographic surgery (MMS).
  • Qualitative analyses showed that high-resolution ultrasound was less likely to identify extension from tumors with subtle areas of extension, such as small foci of dermal invasion from infiltrative SCC and micronodular BCC.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Basal Cell / ultrasonography. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / ultrasonography. Mohs Surgery. Skin Neoplasms / surgery. Skin Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018815.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR051125
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS483270; NLM/ PMC4348076
  •  go-up   go-down


59. Betti R, Radaelli G, Mussino F, Menni S, Crosti C: Anatomic location and histopathologic subtype of basal cell carcinomas in adults younger than 40 or 90 and older: any difference? Dermatol Surg; 2009 Feb;35(2):201-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic location and histopathologic subtype of basal cell carcinomas in adults younger than 40 or 90 and older: any difference?
  • BACKGROUND: Differences in age, site, and histopathologic subtype exist in basal cell carcinoma (BCC).
  • The site was classified as head and neck, trunk, or limbs and the subtype as nodular, superficial, or morpheic-infiltrative.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / epidemiology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215256.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Al-Arashi MY, Salomatina E, Yaroslavsky AN: Multimodal confocal microscopy for diagnosing nonmelanoma skin cancers. Lasers Surg Med; 2007 Oct;39(9):696-705
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total we imaged, analyzed, and compared to histology at least 10 samples of each tumor-type including nodular basal cell carcinoma (BCC), infiltrative basal cell carcinoma, and squamous cell carcinoma (SCC).
  • [MeSH-minor] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Coloring Agents. Diagnosis, Differential. Equipment Design. Humans. In Vitro Techniques. Methylene Blue. Staining and Labeling. Tolonium Chloride

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17960751.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride; T42P99266K / Methylene Blue
  •  go-up   go-down


61. Valeri RM, Kaplanis K, Apostolou T, Kiziridou A, Pantidou A, Boussoulegas A, Destouni Ch: Basaloid squamous cell carcinoma of the uterine cervix with an uncommon metastasis to the left iliac region--case report. Eur J Gynaecol Oncol; 2006;27(6):625-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the uterine cervix with an uncommon metastasis to the left iliac region--case report.
  • We describe a rare and interesting case of a basaloid squamous cell carcinoma (BSC) of the uterine cervix with metastasis in the left iliac region diagnosed by fine needle aspiration (FNA).
  • The material was processed by conventional liquid based cytology (ThinPrep), and by the cell-block technique and diagnosis was based on the cytomorphologic and immunochemical characteristics as well as the patient's history.
  • The cytologic diagnosis concerned a poorly differentiated squamous cell carcinoma.
  • The histological diagnosis then was an "infiltrative squamous cell carcinoma of basaloid type" of the uterine cervix.
  • Our case is of particular interest because it is a rare type of neoplasm with an unusual site of metastasis after a long disease-free period.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Pelvic Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasms, Basal Cell / secondary. Neoplasms, Basal Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290600.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


62. Hudson E, Rashid M, Carter AC, Lester JF: Basaloid carcinoma of the prostate: a case report and review of the literature. Eur J Cancer Care (Engl); 2008 Sep;17(5):509-11
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid carcinoma of the prostate: a case report and review of the literature.
  • Malignant tumours arising from the basal cells of the prostate gland are extremely rare, and the majority of reports in the literature suggest a relatively indolent clinical course.
  • We report a case of infiltrative basaloid carcinoma of the prostate in a 68-year old man that did not respond to systemic chemotherapy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616505.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 7
  •  go-up   go-down


63. Fischer S, Breuninger H, Metzler G, Hoffmann J: Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor. J Craniofac Surg; 2005 Jan;16(1):53-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor.
  • Microcystic adnexal carcinoma (MAC) belongs to the spectrum of locally aggressive adnexal carcinomas and most commonly occurs in the head and neck region.
  • The authors report the case of a 78-year-old woman in whom a diagnosis of MAC was made when a tumor on the right cheek recurred for the second time.
  • Previous histopathologic diagnoses were squamous cell carcinoma and desmoplastic trichoepithelioma.
  • The reported case demonstrates the difficulties in diagnosing MAC and indicates that MAC should always be considered in the differential diagnosis of slowly growing tumors in the head and neck region.
  • If MAC is diagnosed too late, it can be inoperable because of its infiltrative growth.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasms, Basal Cell / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699645.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Sasaki Y, Tsuda H, Ueda S, Asakawa H, Seki K, Murata T, Kuriki K, Tamai S, Matsubara O: Histological differences between invasive ductal carcinoma with a large central acellular zone and matrix-producing carcinoma of the breast. Pathol Int; 2009 Jun;59(6):390-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological differences between invasive ductal carcinoma with a large central acellular zone and matrix-producing carcinoma of the breast.
  • Carcinoma with a large central acellular zone (central acellular carcinoma, CAC) and matrix-producing carcinoma (MPC) have been recently noted as basal-like-type breast cancers, but the two entities are often confused.
  • (ii) alteration of cancer cell adhesion in the transitional area between cellular and acellular zones;.
  • All CAC had relatively sharp margins but showed infiltrative growth accompanied by eosinophilic intercellular matrix.
  • In CAC there was abrupt transition between peripheral cellular and central acellular zones without alteration of cancer cell adhesion.
  • In MPC there was gradual transition from cellular to acellular areas with gradual loss of cancer cell adhesion.
  • It is suggested that CAC and MPC are histologically distinct entities, and that the aforementioned features are helpful for differential diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490469.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


65. Chaux A, Tamboli P, Ayala A, Soares F, Rodríguez I, Barreto J, Cubilla AL: Warty-basaloid carcinoma: clinicopathological features of a distinctive penile neoplasm. Report of 45 cases. Mod Pathol; 2010 Jun;23(6):896-904
MedlinePlus Health Information. consumer health - Genital Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warty-basaloid carcinoma: clinicopathological features of a distinctive penile neoplasm. Report of 45 cases.
  • Most penile cancers are squamous cell carcinomas, but there are several subtypes with different clinicopathologic, viral, and outcome features.
  • We are presenting 45 cases of a distinctive morphological variant of penile squamous cell carcinoma composed of mixed features of warty and basaloid carcinomas.
  • (1) the most common, observed in two-thirds of the cases was that of a typical condylomatous tumor on surface and basaloid features in deep infiltrative nests;.
  • (2) in 15% of the cases, there were non-papillomatous invasive carcinoma nests with mixed basaloid and warty features; and (3) unusually, predominantly papillomatous.
  • Warty-basaloid carcinomas are morphologically distinctive human papillomavirus-related penile neoplasms that, such as basaloid carcinomas, are biologically more aggressive than typical warty carcinoma from which they should be distinguished.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Condylomata Acuminata / pathology. Penile Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Brazil. Cell Differentiation. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Papillomaviridae / pathogenicity. Paraguay. Prognosis. Retrospective Studies. Texas. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305615.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


66. Cabral ES, Cassarino DS: Desmoplastic tricholemmoma of the eyelid misdiagnosed as sebaceous carcinoma: a potential diagnostic pitfall. J Cutan Pathol; 2007 Dec;34 Suppl 1:22-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic tricholemmoma of the eyelid misdiagnosed as sebaceous carcinoma: a potential diagnostic pitfall.
  • BACKGROUND: Sebaceous carcinoma (SC) most commonly presents on the eyelid and is frequently misdiagnosed both clinically and pathologically.
  • Histologic examination showed a lobular, folliculocentric proliferation of palely eosinophilic to clear cells surrounded by peripheral basal cells with palisading.
  • The central portion of the lesion appeared infiltrative with clear cells surrounded by a thickened basement embedded in a dense, collagenous stroma.
  • Therefore, DTL should enter the differential diagnosis of clear-cell neoplasms on the eyelid.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Eyelid Neoplasms / diagnosis. Hair Diseases / diagnosis. Hair Follicle / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Glycogen / metabolism. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997733.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 9005-79-2 / Glycogen
  •  go-up   go-down


67. Shah RB, Magi-Galluzzi C, Han B, Zhou M: Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am J Surg Pathol; 2010 Apr;34(4):470-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
  • Atypical cribriform lesions of the prostate (ACL) are cribriform glands lined by cytologically malignant cells with partial or complete basal cell lining.
  • They represent cribriform high-grade PIN (cribriform HGPIN), which can be an isolated finding not associated with PCa (isolated ACL), or "intraductal carcinoma (IDC-P)" that is almost always associated with infiltrative high-grade prostate carcinoma (PCa) (cancer-associated ACL, ACL-PCa).
  • We report the incidence, topographic relation to cancer, and morphologic differences of these 2 lesions in radical prostatectomy and discuss the potential biologic basis and implication for diagnosis in prostate biopsy.
  • ACL was defined as cribriform glands comprising cytologically malignant cells that spanned the entire glandular lumens with partial or complete basal cell lining confirmed by basal cell immunostaining.
  • ACL intermixed with, or within 3 mm from the border of infiltrative PCa was categorized as ACL-PCa and was considered to be equivalent to IDC-P.
  • ACL can be found both in association with PCa or without associated infiltrative PCa.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182345.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Stafanous SN: The switch flap in eyelid reconstruction. Orbit; 2007 Dec;26(4):255-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Eight cases of large full-thickness eyelid defects resulting from excision of tumours such as basal cell carcinoma (bcc), squamous cell carcinoma (scc) and sebaceous gland carcinoma (sgc) were taken for repair using the switch flap technique.
  • RESULTS: Out of the eight cases of eyelid defects, one was from squamous cell carcinoma, three were from sebaceous gland carcinoma, and four were from infiltrative basal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097963.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Massari LP, Kastelan M, Gruber F: Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol; 2007 Jan;31 Suppl 1:83-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis.
  • Basal cell carcinoma and squamous cell carcinoma, collectively termed non-melanoma skin cancers are the most common malignant tumors in humans.
  • Basal cell carcinoma grows slowly and metastatic spread is very rare.
  • Squamous cell carcinoma is characterized by infiltrative, destructive growth and metastasis.
  • The major role in development of skin cancer is given to proapoptotic p53 molecule or tumor suppressor gene which mutation due to UV exposure leads to resistance of DNA-damaged cell to apoptosis.
  • Other proapoptotic molecules such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are strongly expressed in basal cell carcinoma and squamous cell carcinoma that could be explained by the ability of tumor to escape the attack of immune system.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / physiopathology. Carcinoma, Squamous Cell / physiopathology. Neoplasms, Radiation-Induced / physiopathology. Skin Neoplasms / physiopathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469758.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 29
  •  go-up   go-down


70. Scheinfeld N: Review of scalp alopecia due to a clinically unapparent or minimally apparent neoplasm (SACUMAN). Acta Derm Venereol; 2006;86(5):387-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of scalp alopecia due to a clinically unapparent or minimally apparent neoplasm (SACUMAN).
  • Neoplastic cells, both malignant and benign, local occurring and metastatic, can cause alopecia of the scalp.
  • However, the infiltration of neoplastic cells is sometimes not florid; a condition known as "scalp alopecia due to a clinically unapparent or minimally apparent neoplasm" (SACUMAN).
  • The infiltrative nature of such an alopecia can be unapparent or only minimally apparent.
  • The most common neoplasm in which an uncomplicated, minimally or unapparent scalp alopecia occurs and no infiltrate of cancer is suspected is metastatic breast carcinoma.
  • Other causes include squamous and basal cell carcinomas, angiosarcoma, gastric carcinoma, placental site tromphoblastic tumor, and mycosis fungoides.
  • Dermatologists must be aware that in rare cases a bland scalp alopecia can represent a new or recurring, local or metastatic neoplasm.
  • [MeSH-minor] Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Cicatrix / pathology. Hemangiosarcoma / pathology. Humans. Keloid / complications. Keloid / pathology. Lymphoma / pathology. Scalp / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983449.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 56
  •  go-up   go-down


71. Kapucuoglu N, Basak PY, Bircan S, Sert S, Akkaya VB: Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol Res Pract; 2009;205(2):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the pattern of expression of galectin-3 in cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), and its correlation with the grade of differentiation in SCC and tumor size.
  • Cytoplasmic galectin-3 immunoreactivity was significantly higher in SCC than in both circumscribed and infiltrative BCCs, but no difference was detected between these two types of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Galectin 3 / biosynthesis. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951731.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


72. Lin M, Chen ZQ, Bao Y, Li Q, Du ZG, Xu ZD, Tang F: [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis]. Zhonghua Bing Li Xue Za Zhi; 2010 Jun;39(6):372-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and twenty-eight cases of infiltrative ductal carcinoma were studied using immunohistochemical staining with an antibody panel of ER, PR, HER2 and CK5/6 and subclassified referring to previous reports, and the 9 cases of HER2 positive subtype were tested using FISH.
  • All cases were subclassified into five subgroups, with luminal A (55%), luminal B (20%), HER2 positive (7%), basal-like (10%) and unclassified cases (8%).
  • It was demonstrated that the luminal A group was associated with the best prognosis but the basal-like group worst by univariate analysis.
  • CONCLUSION: According to the expression of ER, PR, HER2 and CK5/6, infiltrative ductal carcinoma could be subclassified into five subgroups with different biological features and outcome, having a role in evaluating the prognosis and guiding the clinical treatment.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Ductal, Breast / classification. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Female. Follow-Up Studies. Humans. Keratin-5 / metabolism. Keratin-6 / metabolism. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Progesterone / metabolism. Survival Rate. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055152.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Keratin-5; 0 / Keratin-6; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


73. Wolf IH, Kodama K, Cerroni L, Kerl H: Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol; 2007 Jun;29(3):237-41
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical imiquimod (IQ) is an effective treatment for genital warts and various malignant tumors of the skin.
  • We investigated the composition of the inflammatory cell infiltrate before, during, and after the treatment of 10 superficial cutaneous malignancies (melanoma in situ (n = 4), melanoma metastasis (n = 1), squamous cell carcinoma in situ (n = 4), and basal cell carcinoma (n = 1) with 5% IQ cream.
  • These findings further support previous investigations that the antitumor effects of IQ result from an enhanced cytotoxic T-cell mediated immune response and from the recruitment of plasmacytoid dendritic cells to the skin.
  • The population of infiltrative inflammatory cells was similar in all patients irrespective of the type of tumor.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bowen's Disease / chemistry. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma in Situ / chemistry. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Female. Humans. Hutchinson's Melanotic Freckle / chemistry. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Keratosis / drug therapy. Keratosis / metabolism. Keratosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519620.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Biomarkers, Tumor; 99011-02-6 / imiquimod
  •  go-up   go-down


74. Reszec J, Sulkowski S: The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. Int J Mol Med; 2005 Oct;16(4):559-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate P53 protein expression and to detect HPV in the tissue samples of 45 benign (papillomas) and 38 malignant conjunctival and eyelid lesions (27 basal cell carcinomas and 11 squamous cell carcinomas).
  • We revealed P53 protein expression in 30 out of 45 (66.6%) squamous cell papillomas.
  • Malignant type HPV 16 and 18 were detected in three squamous cell papillomas, two BCCs and one SCC.
  • However, we observed P53 protein expression in only two HPV-positive papillomas and one infiltrative type of BCC.
  • P53 is probably involved in the development of conjunctival and eyelid tumors due to its high rate of presence in both benign and malignant neoplasms of these organs.
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Humans. Middle Aged. Papilloma / metabolism. Papilloma / pathology. Papilloma / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142387.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Hussein MR: Skin cancer in Egypt: a word in your ear. Cancer Biol Ther; 2005 May;4(5):593-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions included 21 melanomas, 39 squamous cell carcinomas (SCCs), and 202 basal cell carcinomas (BCCs).
  • RESULTS: Skin cancer represented 5% of the malignant tumors of the entire body.
  • Melanomas, BCCs and SCCs were of nodular, keratotic invasive and nodular infiltrative types, respectively.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Egypt / epidemiology. Female. Humans. Incidence. Male. Melanoma / epidemiology. Melanoma / pathology. Middle Aged. Nigeria / epidemiology. Registries. Tanzania / epidemiology. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908785.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Fletcher KC Jr, Shonka DC Jr, Russell MA, Park SS: Defects of the nasal internal lining: etiology and repair. Arch Facial Plast Surg; 2005 May-Jun;7(3):189-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To analyze risk factors leading to full-thickness (FT) defects, to review methods of repair, and to present guidelines for management of aggressive basal cell carcinomas (BCCs) of the nose.
  • CONCLUSIONS: Internal lining defects are more likely to occur from aggressive histologic subtypes of BCC (infiltrative, morpheaform, and micronodular) than nonaggressive subtypes (P < .05).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nasal Mucosa / surgery. Nose Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps
  • [MeSH-minor] Esthetics. Female. Follow-Up Studies. Humans. Male. Nasal Cavity / physiopathology. Nasal Cavity / surgery. Neoplasm Staging. Retrospective Studies. Risk Assessment. Treatment Outcome. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897409.001).
  • [ISSN] 1521-2491
  • [Journal-full-title] Archives of facial plastic surgery
  • [ISO-abbreviation] Arch Facial Plast Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Garavello W, Maggioni D, Nicolini G, Motta L, Tredici G, Gaini R: Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study. Oncol Rep; 2010 Oct;24(4):1073-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advances in clinical treatment of head and neck squamous cell carcinoma (HNSCC) are hampered by its high infiltrative potential leading to distal metastasis.
  • Since their ability to degrade the basal lamina and extracellular matrix, matrix metalloproteinases (MMP) have a pivotal role in tumor invasion.
  • It has been demonstrated that MMP2/9 expression is negative regulated by extracellular signal regulated kinase 1 and 2 (ERK1/2) in HNSCC cell lines.
  • ERKs are protein kinases belonging to the mitogen-activated protein kinases family, and they are involved in the regulation of different cellular aspects, from apoptosis to cell proliferation and differentiation.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Head and Neck Neoplasms / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811691.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.11.24 / MAPK1 protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


78. Humphrey PA: Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol; 2007 Jan;60(1):35-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of adenocarcinoma in prostate needle biopsy tissue.
  • For patients with clinically localised prostate cancer, the diagnosis is typically established by histopathological examination of prostate needle biopsy samples.
  • Major and minor criteria are used to establish the diagnosis, based on the microscopic appearance of slides stained using haematoxylin and eosin.
  • Major criteria include an infiltrative glandular growth pattern, an absence of basal cells and nuclear atypia in the form of nucleomegaly and nucleolomegaly.
  • In difficult cases, basal cell absence may be confirmed by immunohistochemical stains for high-molecular-weight cytokeratins (marked with antibody 34betaE12) or p63, which are basal cell markers.
  • Cocktails of antibodies directed against basal cell markers and AMACR are particularly useful in evaluating small foci of atypical glands, and in substantiating a diagnosis of a minimal adenocarcinoma.
  • Measures of tumour extent are (1) number of cores positive for cancer in the number of cores examined, (2) percentage of needle core tissue affected by carcinoma and (3) linear millimetres of carcinoma present.
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jan;124(1):98-107 [10629139.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Prostate. 2003 Mar 1;54(4):290-8 [12539227.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):365-71 [12604893.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):432-40 [12657927.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):630-5 [12861057.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] Prostate. 2003 Oct 1;57(2):93-8 [12949932.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):220-5 [14983935.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):328-48 [14976539.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):292-306 [14976540.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):701-5 [15166661.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):739-44 [15280928.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1224-9 [15316323.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1180-90 [15205683.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • [Cites] J Urol. 1980 May;123(5):686-8 [6158582.001]
  • [Cites] Am J Clin Pathol. 1983 Dec;80(6):850-4 [6195916.001]
  • [Cites] J Urol. 1986 Mar;135(3):507-9 [2418218.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):330-4 [1996542.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):618-23 [7684998.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):368-74 [7506797.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):260-4 [7510946.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):796-803 [8037294.001]
  • [Cites] Urology. 1994 Sep;44(3):371-6 [7521093.001]
  • [Cites] Hum Pathol. 1995 Feb;26(2):223-9 [7860053.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Arch Pathol Lab Med. 1995 May;119(5):444-7 [7748073.001]
  • [Cites] Urology. 1995 Jun;45(6):981-6 [7539563.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):419-26 [8604808.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):376-81 [8674022.001]
  • [Cites] Urology. 1997 Mar;49(3A Suppl):16-22 [9123731.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):566-76 [9158682.001]
  • [Cites] Hum Pathol. 1998 May;29(5):543-6 [9596281.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1073-7 [9737239.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):918-24 [10435561.001]
  • [Cites] AMA Arch Pathol. 1953 Feb;55(2):131-41 [13007281.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1462-8 [15619204.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):579-87 [15832080.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] J Urol. 2005 Jul;174(1):121-5 [15947595.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):874-80 [15958851.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):20-33 [16019757.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1159-63 [16096404.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):708-15 [16203278.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):287-90 [16341144.001]
  • [Cites] Urology. 2001 Oct;58(4):619-24 [11597556.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Histopathology. 2002 Jul;41(1):35-41 [12121235.001]
  • (PMID = 17213347.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 74
  • [Other-IDs] NLM/ PMC1860598
  •  go-up   go-down


79. Jie G, Zhixiang S, Lei S, Hesheng L, Xiaojun T: Relationship between expression and methylation status of p16INK4a and the proliferative activity of different areas' tumour cells in human colorectal cancer. Int J Clin Pract; 2007 Sep;61(9):1523-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The p16(INK4a) gene is a cell cycle inhibitor and a major tumour suppressor protein, but the regulation and effects on tumour cells' invasion process of p16(INK4a) is poorly known.
  • A role for p16(INK4a) in basal cell carcinoma is suggested by the observation that p16(INK4a) was upregulated at the invasive front of the majority of basal cell carcinomas with infiltrative growth patterns, accompanied by cessation of proliferation.
  • The expressions of the proliferating cell nuclear antigen ki67 and p16(INK4a) were assessed by immunohistochemistry, methylation-specific polymerase chain reaction (MS-PCR) and reverse-transcription polymerase chain reaction (RT-PCR) in the different areas.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Gene Expression. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Methylation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537196.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


80. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI: Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol; 2008 Mar;32(3):461-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant diffuse expression of p63 in prostate carcinoma cells is a rare and poorly understood phenomenon.
  • The presence of p63 positive atypical glands with an infiltrative pattern and perineural invasion on radical prostatectomy confirmed the needle biopsy diagnosis of carcinoma.
  • Rarely, prostate cancer can aberrantly express diffuse p63 staining in a nonbasal cell distribution leading to the erroneous diagnosis of atrophy or atypical basal cell proliferation.
  • The diagnosis of prostate cancer is based on the morphology and confirmed by the absence of high molecular weight cytokeratin staining and positivity for alpha-methylacyl-CoA racemase in the atypical glands.
  • Pathologists need to be aware of this rare and unusual phenomenon, which is a potential pitfall in prostate cancer diagnosis.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300803.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


81. Janković-Velicković L, Katić V, Ignjatović I: [Morphological markers of secretory activity in prostatic adenocarcinoma]. Vojnosanit Pregl; 2007 Sep;64(9):617-22
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnosis of prostate cancer relies on the infiltrative growth pattern, presence of macronucleoli, and absence of basal cell layer.
  • All morphological signs were detected in carcinoma of Gleason grade 1-4A.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969817.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


82. Ben Simon GJ, Schwarcz RM, Douglas R, Fiaschetti D, McCann JD, Goldberg RA: Orbital exenteration: one size does not fit all. Am J Ophthalmol; 2005 Jan;139(1):11-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis included orbital, ocular, and adnexal malignancies, with squamous and basal cell carcinoma being the most common.
  • CONCLUSIONS: Clinical indications for orbital exenteration remain similar over the last four decades with a higher prevalence of squamous cell carcinoma in our institute.
  • Orbital exenteration is considered curative in cases of basal or squamous cell carcinoma but not in cases of malignant infiltrative processes such as adenoid cystic carcinoma of the lacrimal gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2005 Jan;139(1):152-3 [15652840.001]
  • (PMID = 15652823.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Heppt W: [Skin tumors in facial plastic surgery]. HNO; 2009 Apr;57(4):324-35
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histologic findings are actinic keratosis and basal cell carcinoma.
  • In patients with recurrent or deeply infiltrative tumors, reconstructive procedures of the facial nerve, parotid duct, and lacrimal duct might be needed.
  • [MeSH-major] Facial Neoplasms / diagnosis. Facial Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / trends. Reconstructive Surgical Procedures / trends. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Feb;99(2):136-41 [15660081.001]
  • [Cites] Laryngoscope. 1990 Mar;100(3):313-9 [2308457.001]
  • [Cites] HNO. 1998 Jun;46(6):569-78 [9677488.001]
  • [Cites] Plast Reconstr Surg. 2008 Jul;122(1):240-3 [18594411.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Dec;4(12):1080-4 [17176417.001]
  • [Cites] HNO. 2007 Jun;55(6):497-510 [17486306.001]
  • [Cites] Klin Monbl Augenheilkd. 1988 Dec;193(6):647-50 [3065572.001]
  • [Cites] Plast Reconstr Surg. 1967 May;39(5):472-7 [5336914.001]
  • [Cites] Plast Reconstr Surg. 2007 Oct;120(5):1171-207; discussion 1208-16 [17898591.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 Aug;221(8):609-14 [15343443.001]
  • [Cites] Br J Plast Surg. 1962 Jul;15:242-54 [13871292.001]
  • [Cites] Adv Exp Med Biol. 2008;624:89-103 [18348450.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):144-8 [9754642.001]
  • [Cites] Plast Reconstr Surg. 2008 Feb;121(2):458-65 [18300962.001]
  • [Cites] GMS Curr Top Otorhinolaryngol Head Neck Surg. 2007;6:Doc02 [22073078.001]
  • [Cites] Dermatol Surg. 2000 Mar;26(3):215-8 [10759796.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jul;385(4):284-9 [10958513.001]
  • (PMID = 19347378.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


84. Abedalthagafi M, Rushing EJ, Auerbach A, Desouki MM, Marwaha J, Wang Z, Fanburg-Smith JC: Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases. Ann Diagn Pathol; 2010 Feb;14(1):15-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous angiosarcoma (AS) is a rare malignant neoplasm of dermis composed of infiltrating cells of endothelial phenotype with overall poor prognosis.
  • Associated basal cell carcinoma was noted in 1 patient; no others had other neoplasms or unrelated surgeries.
  • All cases demonstrated infiltrative growth pattern, cytologic atypia, and mitotic activity, including atypical forms.
  • CD31 highlighted malignant endothelial cells.
  • Requirement for diagnosis includes extravascular proliferation of atypical endothelial cells with mitotic activity in vasoformative, solid, and papillary patterns.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anoxia / metabolism. Anoxia / pathology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20123452.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


85. Vollmer RT: Panel vs. single marker for discriminating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma. J Cutan Pathol; 2009 Feb;36(2):283; author reply 284
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panel vs. single marker for discriminating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Keratin-20 / biosynthesis. Neoplasms, Basal Cell / metabolism. Receptors, Androgen / biosynthesis. Skin Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Cutan Pathol. 2008 Feb;35(2):174-9 [18190441.001]
  • (PMID = 19208081.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Receptors, Androgen
  •  go-up   go-down


86. Sambandan PG, Goldman GD: Infiltrative basal cell carcinomas presenting as actinic keratosis: implications for clinical practice. Dermatol Surg; 2008 Jan;34(1):9-13; discussion 13-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrative basal cell carcinomas presenting as actinic keratosis: implications for clinical practice.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Keratosis / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Mohs Surgery. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053057.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Bozikov K, Taggart I: Metastatic basal cell carcinoma: is infiltrative/morpheaform subtype a risk factor? Eur J Dermatol; 2006 Nov-Dec;16(6):691-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: is infiltrative/morpheaform subtype a risk factor?
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Incidence. Neoplasm Metastasis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229614.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] France
  •  go-up   go-down






Advertisement